Early clinical experience with flesinoxan, a new selective 5-HT1A receptor agonist

  • J. M. de Voogd
  • G. Prager
Part of the Developments in CardioCardiovascular Pharmacology of 5-Hydroxytryptamine book series (DICM, volume 106)


Flesinoxan hydrochloride has been shown in pharmacological experiments to be a potent and selective 5-HT1A receptor agonist with centrally-mediated antihypertensive properties. Flesinoxan lowers blood pressure in various species, and the effect lasts for more than four hours after a single administration [1]. The cardiovascular profile of the compound includes a reduction of total peripheral resistance, a small, vagally mediated decrease in heart rate, little or no effect on cardiac output, no direct negative inotropic effect and strong renal vasodilatation. Further, no orthostatic hypotension or tachyphylaxis has been found [1, 2]. In the investigation reported here flesinoxan has been studied in normotensive and hypertensive human subjects. Special attention was paid to cardiovascular parameters, safety, tolerability, psychometric performance and pharmacokinetics of the drug after single and repeated doses.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hartog J, Wouters W (1988): Flesinoxan hydrochloride. Drugs of the future 13: 31–33.Google Scholar
  2. 2.
    Wouters W, Hartog J, Bevan P (1988): Flesinoxan. Cardiovasc. Drug Reviews 6: 71–83.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1990

Authors and Affiliations

  • J. M. de Voogd
  • G. Prager

There are no affiliations available

Personalised recommendations